Se încarcă compania
Just reported
Q4 FY2026 results
From Cencora's results release of 4 noiembrie 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
88,35B USD
+5,5 % y/y
+4,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
2,71 USD
-31 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
906,8M USD
-19 % q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted19,40 USD – 19,75 USDFirst given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Situațiile financiare complete →
Construit din raportările proprii ale Cencora, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
